New flu pill for teens shows promise in Late-Stage trial

NCT ID NCT07229547

Recruiting now Symptom relief Sponsor: Ruijin Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 16, 2026 · Updated 2 times

Summary

This study tests a new flu medicine called onradivir in teenagers aged 12 to 17 with uncomplicated influenza A. About 150 teens will receive either the drug or a placebo for 5 days. Researchers will track how fast flu symptoms like fever and body aches go away, and check for side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Onradivir
What this could lead to: If it works, this could provide a new treatment option to help teenagers recover faster from the flu.
What could go wrong: This is an early-stage Phase 3 trial with only 150 participants, so results may not apply to everyone. The drug may not work better than a placebo, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INFLUENZA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

influenza swine influenza

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

INFLUENZA

Contacts and locations

Locations

Ruijin Hospital
RECRUITING

Shanghai, Shanghai Municipality, 200025, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.